Honestly I could care less about the MJFF grants going forward. I agree that the grants are good but this company is setting itself up for a partnership deal with a larger biopharma company. The writing is on the wall. Rubinfeld and the other senior execs from Bayer, Bristol Myers and Pfizer that are on the board will bring a deal to them. A partnership with a bigger pharma company that includes a license deal will allow them to fund the trials at the partner's expense while giving up a license / royalty on sales.
The $13 Million market cap is a joke. MANF is currently producing significantly better results than GDNF was at this stage of testing when the company that owned it was bought out for $250 Million. I believe AMBS will be at a $100 Million market cap within a year and probably within 6 months.
People who are still doubting this need to ask themselves a few questions:
(1) Why is the co-founder of Amgen wasting his time here? This is a guy with a ridiculously impressive resume. Co-Founder of Amgen, founder of Supergen, invented Amoxicillin.
(2) Why is he presenting along with the CSO, John Commissiong, at a biotech conference known for bringing VC and bigger pharma investors to biotech startups?
(3) Why did the co-Founder of Amgen state that MANF could be the biggest success he has ever seen in his career?
(4) And why did Hermo Pharma, a VC backed and MJFF funded biotech in the same exact field as AMBS, challenge their patents? Why would they say that their patent protection is too broad and causes an undue burden on anyone trying to test for any variant of MANF?
Again, I'm not going to waste my time listening to some college kids on this board with their $3,000 in life savings trying to bash the stock. Get lost. I'd rather spend my time listening to guys like the co-founder of Amgen. I know it's crazy but I think they have just a little more knowledge about this patent protected drug.
Get ready for the fireworks leading into the January presentation. It's going to be very exciting.